



CURRICULUM VITAE

Steven T. Forman, MD, FACC, FSCAI, RVT

Joined Los Alamitos Cardiovascular as partner in 1999

Managing Partner since 2005

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | website: <http://www.losalcardio.com>

<p>Specialties:</p>	<p>Cardiovascular Diseases, Interventional Cardiology, Endovascular Diseases, Venous and Lymphatic Medicine</p>
<p>Board Certifications:</p>	<ul style="list-style-type: none"> • Certified in Venous and Lymphatic Medicine American Board of Venous and Lymphatic Medicine (ABVLM) 2012 • Certified in Interventional Cardiology American Board of Internal Medicine 1999 (Recertification 2009) • Certified in Cardiovascular Disease American Board of Internal Medicine 1997 (Recertification 2007) <hr/> <ul style="list-style-type: none"> • Expert Reviewer The Medical Board of California August 2014 – Present
<p>Additional Certifications:</p>	<ul style="list-style-type: none"> • GCP Certified July 2010 CITI Collaborative Institutional Training Initiative
<p>Research Experience:</p>	<ul style="list-style-type: none"> • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction. Principal Investigator 2017 Sponsor: Amgen NCT02929329: https://clinicaltrials.gov/ct2/show/NCT02929329

- **PROVE-HF:** A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
 Sub-Investigator | 2017
 Sponsor: Novartis
 NCT02887183: <https://clinicaltrials.gov/ct2/show/NCT02887183>
- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
 Principal Investigator | 2016 – Present
 Sponsor: CVRx, Inc.
 NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>
- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
 Principal Investigator | 2016
 Sponsor: Gilead/ICON
- **THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
 Sub-Investigator | 2015 – Present
 Sponsor: AstraZeneca
 NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>
- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
 Sub-Investigator | 2015
 Sponsor: Amgen, Evidera
- **DECLARE-TIMI 58 Dapagliflozin Effect on Cardiovascular Events:**
 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to

Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Principal Investigator | 2013 – Present

Sponsor: AstraZeneca

NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>

- **ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Sub-Investigator | 2013 – Present
Sponsor: Sanofi
NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>
- **SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**
Sub-Investigator | 2013 – 2017
Sponsor: Yale University School of Medicine/NIH
NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>
- **RivaroxAFL3003:** An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
Principal Investigator | 2013
Sponsor: Janssen Scientific Affairs/Johnson & Johnson
- **Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.**
Principal Investigator | 2013
Sponsor: Tasly Pharmaceuticals
NCT0169580 | <http://clinicaltrials.gov/ct2/show/NCT0169580>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
Principal Investigator | 2013 – Present
Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women's Hospital/National Heart Lung and Blood Institute

NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>

- **User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.**

Principal Investigator | 2012

Sponsor: Alere San Diego

- **Mission® PT Coagulation Monitoring System Clinical Study.**

Sub-Investigator | 2012

Sponsor: ACON Laboratories, INC.

- **The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.**

Principal Investigator | 2012 – 2015

Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)

NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>

- **GLORIA-AF 1160.129:** Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.

Principal Investigator | 2012 – Present

Sponsor: Boehringer Ingelheim

NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>

- **California State Elective Percutaneous Coronary Intervention Pilot Program**

Principal Investigator | 2010 – 2014

- **BRADY-CARE:** Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.

Sub-Investigator | 2010 – 2012

Sponsor: St. Jude Medical Center

NCT01062126 | <http://clinicaltrials.gov/ct2/show/NCT01062126>

- **The PROMISE Trial:** PROspective Multicenter Imaging Study for Evaluation of Chest Pain.

Principal Investigator | 2010 – 2014

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

NCT01174550 | <http://clinicaltrials.gov/ct2/show/record/NCT01174550>

- **ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Principal Investigator | 2010 – Present
Sponsor: Janssen Scientific Affairs, LLC
Collaborator: Duke Clinical Research
NCT01165710 | <http://clinicaltrials.gov/ct2/show/NCT01165710>
NCT01701817 | <http://clinicaltrials.gov/ct2/show/NCT01701817>
- **RATE:** Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00837798 | <http://clinicaltrials.gov/ct2/show/NCT00837798>
- **FREEDOM:** A Frequent Optimization Study the Quick Opt™ Method.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00418314 | <http://clinicaltrials.gov/ct2/show/NCT00418314>
- **ENGAGE:** Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
Principal Investigator | 2009 – 2015
Sponsor: Daiichi Sankyo Pharma Development
NCT00781391 | <http://clinicaltrials.gov/ct2/show/record/NCT00781391>
- Phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of Dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV Risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (Dal-ACUTE).
Principal Investigator | 2008 – 2012
Sponsor: F. Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc. , Roche Global Development.
NCT01323153 | <http://clinicaltrials.gov/ct2/show/NCT01323153>
- Multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in treating iron deficiency anemia in subjects who are not dialysis dependent.
Principal Investigator | 2007 – 2009
Sponsor: Luitpold Pharmaceuticals, Inc.
NCT00704028 | <http://clinicaltrials.gov/ct2/show/NCT00704028>

	<ul style="list-style-type: none"> • Systolic and diastolic myocardial dysfunction during endotoxemia in pigs. Proctor: Roy D Goldfarb, PhD 1989 – 1991 Department of Physiology, Albany Medical College
<p>Current Hospital Appointments:</p>	<ul style="list-style-type: none"> • Los Alamitos Medical Center 3751 Katella Avenue Los Alamitos, California 90720 • MemorialCare Health System Long Beach Memorial Medical Center 2801 Atlantic Avenue Long Beach, California 90801 • Lakewood Regional Medical Center 3700 South Street Lakewood, California 90712
<p>Committees:</p>	<p><i>Los Alamitos Medical Center</i></p> <ul style="list-style-type: none"> • Director of Cardiac Catheterization Lab, Effective March 2014 • Chief of Staff, January 2014 – December 2015 • Chairman of Elective PCI Pilot Program, June 2010– 2014 • Vice Chief of Staff, Medical Executive Committee, January 2012 – December 2013 • Secretary/Treasurer, Medical Executive Committee, January 2010 – December 2011 • Chief of Medicine, January 2007 – December 2010 • Chairman of Allied Health Committee, January 2006 – December 2006 • Member, Medical Executive Committee, January 2006 – Present • Member, Myocardial Infarction Quality Assurance Committee, January 2001 – Present • Member, Cardiovascular Quality Assurance Committee, January 2000 – Present <p><i>State of California</i> Member, AOC (Advisory Oversight Committee) for the Elective PCI (Percutaneous Coronary Interventions) Pilot Program for the State of California, June 2010 – 2014</p>

Professional Societies:	<ul style="list-style-type: none"> • American College of Phlebology (RVT) Fellow • American College of Cardiology (FACC) Fellow • American College of Physicians (FACP) Member • Society for Cardiovascular Angiography and Intervention Member • Society of Cardiovascular CT Member • Los Angeles County Medical Association Member • American Medical Association Member
Academic Appointments:	<ul style="list-style-type: none"> • Volunteer Faculty Department of Medicine/Division of Cardiology University of California , Irvine (UCI) November 2011 – Present • Instructor in Medicine Department of Medicine The New York Hospital /Cornell University Medical Center June 1996 – June 1998
Work History:	<ul style="list-style-type: none"> • Los Alamitos Cardiovascular Los Alamitos, California 1999 – Present • Cardiology Associates of North Jersey 1030 Clifton Avenue Clifton, New Jersey 07013 July 1998 – August 1999 • Urgent Care Physician Memorial Sloan Kettering Cancer Center New York, New York July 1994 – June 1996
Previous Hospital Appointments:	<ul style="list-style-type: none"> • General Hospital of Passaic 350 Boulevard Passaic, New Jersey 07055 July 1998 – August 1999 • Saint Mary's Hospital 211 Pennington Avenue Passaic, New Jersey 07055

	<p>July 1998 – August 1999</p> <ul style="list-style-type: none"> • Saint Joseph’s Hospital and Medical Center 703 Main Street Passaic, New Jersey 07055 July 1998 – August 1999 • Chilton Memorial Hospital 97 West Parkway Pomptom Plains, New Jersey 07444 July 1998 – August 1999 • Passaic Beth Israel Hospital 70 Parker Avenue Passaic, New Jersey 07055 July 1998 – August 1999
Publications:	<ul style="list-style-type: none"> • Shaknovich A, Forman ST, Parikh M, Deutsch E, Bergman G, McCaffery T, Newman GC, Tarazona N and Sanborn T. “Novel distal occluder washout methods for prevention of no-reflow during stenting of saphenous vein grafts.” <i>Catheter Cardiovascular Intervention</i>. 1999 Aug: 47(4): 397 – 403. • Marshall ES, Raichlen JS, Forman S, Heyrich GP, Keen WD, Weitz HH. “Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery.” <i>American Journal of Cardiology</i>. 1995 Oct 15: 76(11): 817 – 821.
Education:	<ul style="list-style-type: none"> • Interventional Cardiology Fellowship The New York Hospital – Cornell University Medical Center The Division of Cardiology New York, New York July 1997 – June 1998 • Cardiovascular Diseases Fellowship The New York Hospital – Cornell University Medical Center New York, New York July 1994 – June 1997 • Internal Medicine Internship and Residency Thomas Jefferson University Hospital Department of Medicine Philadelphia, Pennsylvania July 1991 – June 1994

- | | |
|--|--|
| | <ul style="list-style-type: none">• Medical Education
Albany Medical College
Albany, New York
MD, May 1991
• Undergraduate Education
The Johns Hopkins University
Baltimore, Maryland
Bachelor of Arts in Natural Science, May 1987 |
|--|--|